Treat Early/Treat Aggressively: Examining a New Paradigm in Diabetes Management
Including proceedings from a roundtable held in Chicago, Illinois
Activity Date: October 2009  — Activity Info: Volume6, (6)
Goals & Objectives | Faculty | Complete Pre-Test Activity | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired)


To provide managed care and community pharmacists with up-to-date information regarding their role in managing patients with type 2 diabetes mellitus.

This activity is designed for managed care and community pharmacists. No prerequisites required.

The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:

  • Explain the defect in incretin secretion in patients with type 2 diabetes mellitus (T2DM).
  • Describe current guidelines for T2DM management and arguments for and against the recommended treatment algorithm.
  • Identify the pharmacodynamics surrounding newly available dipeptidyl peptidase-4 inhibitors and appropriate patient selection criteria.
  • Forecast how ongoing research may ultimately change both our treatment goals and treatment approach to T2DM.

The University of Tennessee College of Pharmacy (UTCOP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) to provide continuing pharmacy education for pharmacists.

acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based educational activity will provide a statement for 2.0 contact hours credit (0.2 CEUs) and will be available for download following successful completion of the activity. Successful completion includes participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination one more time. ACPE Program # 064-000-09-210-H01-P.

This continuing education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean for Continuing Pharmacy Education, University of Tennessee College of Pharmacy.

The estimated time to complete this educational activity: 2 hours.

Release date: October 15, 2009. Expiration date: October 15, 2011.

The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This enduring material is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.

This activity is supported by an independent medical education grant from the Bristol-Myers Squibb and AstraZeneca Pharmaceuticals LP, Alliance Partners.

Home | Contact Us | View Account | Need Help?